| Date | Title | | | 12/23/09 | Raptor Pharmaceutical Corp. Announces Closing of $7.5 Million Registered Direct Offering| NOVATO, Calif., Dec 23, 2009 /PRNewswire-FirstCall via COMTEX/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced that on December 22, 2009, it completed its registered direct offering with institutional investors, raising an aggregate amount of approximately $7.5 million of gross proceeds (before placement agent fees and offering expenses) through the sale of 3,747,558 units. The units consist of one share of common stock and one warrant to purchase 0.5 o... |
|  | | 12/18/09 | Raptor Pharmaceutical Corp. Announces $7.5 Million Securities Offering| NOVATO, Calif., Dec 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced that it has entered into definitive agreements with institutional investors to purchase 3,747,558 units for gross proceeds of approximately $7.5 million, before placement agent fees and offering expenses.
The offering is made pursuant to the Form S-3 shelf registration statement that was filed by Raptor with the Securities and Exchange Comm... |
| | | 11/23/09 | Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain|
NOVATO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP) today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco. The results of the study led by Mark Wallace, M.D., Professor of Clinical Anesthesiology at the ... |
| | | 11/23/09 | Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis| Goal of Trial Achieved Demonstrating Potentially Less Frequent Administration Using Lower Daily Dose
NOVATO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP), today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinica... |
| | | 11/04/09 | Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference| Proof-of-Concept Data at 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain
NOVATO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.
(Log... |
| | | 10/27/09 | Raptor Pharmaceutical Corp. to Present at the 8th Annual BIO Investor Forum|
Starting October 27th, the Company will use NASDAQ Ticker Symbol: RPTP
Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that senior management will present a corporate overview and update at the 8th Annual BIO Investor Forum, to be held October 28-29, 2009 at the Palace Hotel in San Francisco, CA. Raptor's presentation will take place on Thursday, October 29 at 1:00pm in the Pacific Heights room.
(Logo: http://www.newscom.com/cgi-bin/prnh/2007... |
| | | 10/12/09 | Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)|
NOVATO, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population. At the completion of the initial ... |
| | | 10/01/09 | Raptor Pharmaceutical Expands Board of Directors|
NOVATO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the Company's board of directors. Dr. Keltner is currently CEO and President of Light Sciences Oncology, a privately-held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors. He is also CEO of EPISTAT, an international healthcare techn... |
| | | 09/30/09 | Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger| Creates Biopharmaceutical Company Named Raptor Pharmaceutical Corp. to Trade Under NASDAQ Ticker "RPTP"
NOVATO, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) announced today the completion of their merger. The combined company is named "Raptor Pharmaceutical Corp." and will commence trading on September 30, 2009 on the NASDAQ Capital Market under the ticker symbo... |
| | | 09/28/09 | Raptor Pharmaceuticals and TorreyPines Therapeutics Receive Stockholder Approvals to Merge| Merger to Create NASDAQ-Listed Biopharmaceutical Company named Raptor Pharmaceutical Corp.
NOVATO, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that its stockholders approved the proposals to complete the proposed merger with TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) at its annual meeting of stockholders held on Monday, September 28, 2009. Concurrently, at the annu... |
| | | 08/31/09 | Raptor Pharmaceuticals Schedules 2009 Annual Meeting of Stockholders|
NOVATO, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it will hold its 2009 Annual Meeting of Stockholders on Monday, September 28, 2009 at 10:00 a.m. Pacific Time at their corporate offices at 9 Commercial Blvd., Suite 200, Novato, California. All stockholders of record as of August 27, 2009 will be eligible to vote at such annual meeting and all stockholders of Raptor are invited to attend s... |
| | | 08/25/09 | Raptor Pharmaceuticals Raises $5 Million| NOVATO, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has raised an aggregate $5 million of gross proceeds through a private placement of units ("August 2009 Private Placement") and through the exercise of warrants (the "Warrant Exchange") originally issued in connection with its May/June 2008 private placement. The August 2009 Private Placement resulted in gross proceeds to Raptor of approxi... |
| | | 07/28/09 | Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement| NOVATO, Calif. and LA JOLLA, Calif., July 28, 2009 /PRNewswire-FirstCall via COMTEX/ -- Nasdaq-Listed Biopharmaceutical Company Focusing on Improved Drug Targeting and Reformulation of Existing Therapeutic Compounds to Benefit Underserved Patient Populations
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX), today announced that they have entered into a definitive merger agreement. Upon closing, ... |
| | | 07/16/09 | Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family Conference| NOVATO, Calif., July 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that Patrice P. Rioux, M.D., Ph.D., Raptor's Chief Medical Officer, will present an update on the Company's ongoing Phase 2b study of delayed-release cysteamine bitartrate ("DR Cysteamine") for the potential treatment of cystinosis, and its plans for further clinical development of the product candidate, at the Cystinosis Research... |
| | | 06/09/09 | Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier| --Roche to fund evaluation of Raptor's proprietary NeuroTrans(TM) technology
NOVATO, Calif., June 9, 2009 /PRNewswire-FirstCall via COMTEX/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has entered a collaboration and licensing agreement with Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) to evaluate therapeutic delivery across the blood-brain barrier, ("BBB") starting with Raptor's proprietary NeuroTrans(TM) BBB transporter platform.... |
| | | 06/01/09 | Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis| NOVATO, Calif., June 1, 2009 /PRNewswire-FirstCall via COMTEX/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has dosed the first patient in its Phase 2b clinical trial, conducted in collaboration with the University of California, San Diego ("UCSD"), to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic cystinosis ("cystinosis"), a rare genetic lysosomal storage disease. ... |
| | | 04/29/09 | Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTransTM Patent Applications| --Claims to Cover Therapeutic Delivery Across Blood-Brain BarrierNOVATO, Calif., April 29, 2009 /PRNewswire-FirstCall via COMTEX/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP) today announced that the United States Patent and Trademark Office ("USPTO") has issued two Notices of Allowance for U.S. Patent Application Nos. 10/812,849 and 11/202,566, titled "Methods of increasing delivery of active agents to brain comprising administering receptor-associated ... |
| | | 04/13/09 | Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer| Novato, California, April 13, 2009 – Raptor Pharmaceuticals Corp. (“Raptor” or the “Company”) (OTCBB: RPTP) today announced the appointment of Patrice P. Rioux, M.D., Ph.D., as Chief Medical Officer (“CMO”). Dr. Rioux will be responsible for the clinical and regulatory advancement of Raptor’s clinical-stage drug development programs.
Raptor’s clinical programs include Delayed-Release Cysteamine (“DR Cysteamine”) for the potential treatment of nephropathic cystinosis (“cystinosi... |
| | | 02/05/09 | Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)| Study Evaluating Cysteamine in Collaboration with UC San Diego
Novato, California, February 5, 2009 - Raptor Pharmaceuticals Corp.
("Raptor" or the "Company") (OTC Bulletin Board: RPTP),
today announced the completion of patient enrollment in its Phase 2a open-label
clinical trial to evaluate cysteamine bitartrate ("cysteamine") in
patients diagnosed with non-alcoholic steatohepatitis ("NASH"). NASH,
a progressive form of liver disease that accounts for approximately 10% of... |
| |
|
